Eiger BioPharmaceuticals (NASDAQ:EIGR) Issues Earnings Results

Eiger BioPharmaceuticals (NASDAQ:EIGRGet Rating) announced its earnings results on Thursday. The biotechnology company reported ($0.51) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.71) by $0.20, Fidelity Earnings reports. Eiger BioPharmaceuticals had a negative return on equity of 102.48% and a negative net margin of 672.48%. During the same quarter in the previous year, the company earned ($0.57) earnings per share.

Eiger BioPharmaceuticals Trading Down 9.3 %

Eiger BioPharmaceuticals stock traded down $0.90 during trading hours on Friday, reaching $8.75. 728,707 shares of the company were exchanged, compared to its average volume of 249,367. The company has a quick ratio of 3.97, a current ratio of 4.02 and a debt-to-equity ratio of 0.20. The stock has a 50-day moving average of $7.22 and a 200 day moving average of $6.52. Eiger BioPharmaceuticals has a 12 month low of $3.53 and a 12 month high of $10.02.

Institutional Investors Weigh In On Eiger BioPharmaceuticals

A number of large investors have recently added to or reduced their stakes in the stock. State Street Corp boosted its position in shares of Eiger BioPharmaceuticals by 1.5% in the first quarter. State Street Corp now owns 554,315 shares of the biotechnology company’s stock valued at $4,601,000 after acquiring an additional 8,160 shares during the period. Dimensional Fund Advisors LP boosted its position in shares of Eiger BioPharmaceuticals by 35.8% in the first quarter. Dimensional Fund Advisors LP now owns 387,791 shares of the biotechnology company’s stock valued at $3,221,000 after acquiring an additional 102,153 shares during the period. Charles Schwab Investment Management Inc. boosted its position in shares of Eiger BioPharmaceuticals by 2.3% in the first quarter. Charles Schwab Investment Management Inc. now owns 88,711 shares of the biotechnology company’s stock valued at $737,000 after acquiring an additional 1,953 shares during the period. Virtu Financial LLC boosted its position in shares of Eiger BioPharmaceuticals by 139.4% in the first quarter. Virtu Financial LLC now owns 54,493 shares of the biotechnology company’s stock valued at $452,000 after acquiring an additional 31,734 shares during the period. Finally, Walleye Capital LLC bought a new stake in shares of Eiger BioPharmaceuticals in the first quarter valued at approximately $353,000. Institutional investors own 73.78% of the company’s stock.

Eiger BioPharmaceuticals Company Profile

(Get Rating)

Eiger BioPharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of targeted therapies for rare and ultra-rare diseases in the United States and internationally. Its lead product candidate is Lonafarnib, an orally bioavailable, small molecule, which is in Phase III clinical trials to treat hepatitis delta virus infection.

Read More

Earnings History for Eiger BioPharmaceuticals (NASDAQ:EIGR)

Receive News & Ratings for Eiger BioPharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eiger BioPharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.